Molecularly Tailored Therapy for Pancreas Cancer

• Status: Completed
• Trial end date: 2018-01-24
• Target enrollment: 0
• Participant gender: All

Summary

Patient therapy is tailored according to the molecular profile of the patient's tumor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Georgetown University
• Treatments: Camptothecin; Docetaxel; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Levoleucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Histologically proven pancreatic adenocarcinoma with measurable disease

• Biopsy accessible tumor deposits

• ECOG performance status 0-2

• Age >/= 18 years

• Subjects with no brain metastases or history of previously treated brain metastases

• Adequate hepatic, renal, and bone marrow function

• Partial thromboplastin time must benormal range and INR < 1.5

• Life expectancy > 12 weeks

• Women of childbearing potential must have a negative seum pregnancy test within 14 days prior to initiation of treatment

• Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the consents

Exclusion Criteria:

• CNS metastases which do not meet criteria outlines in inclusion criteria

• Active severe infection or known chronic infection with HIV or hepatitis B virus

• Cardiovascular disease

• Life threatening visceral disease or other severe concurrent disease

• Women who are pregnant, breastfeeding, or women of childbearing potential not using dual forms of effective contraception

• Anticipated patient survival under 3 months

• Patients receiving any other investigational agents

• History of allergic reactions attributed to compounds of similar chemical or biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan

• Uncontrolled intercurrent illness